Astal Laboratories Limited has announced the allotment of 14,70,000 equity shares upon the conversion of warrants by persons belonging to the non-promoter category. The decision was approved by the Board of Directors during a meeting held on May 12, 2026, at the company's corporate office in Telangana.

The equity shares have been issued at a price of ₹40 each, which includes a face value of ₹10 and a premium of ₹30 per share. The company received the remaining 75% of the issue price, totaling ₹4,41,00,000, upon the conversion of these warrants. The warrants were originally allotted on a preferential basis on November 27, 2024.

Allotment Details

The preferential issue was made to 11 strategic investors classified as non-promoters. The allotment was conducted following a special resolution passed by shareholders at the Annual General Meeting held on August 5, 2024, and subsequent in-principle approval from BSE Limited.

Capital Structure Update

Consequent to this allotment, the paid-up equity capital of astal laboratories has increased. The capital has risen from ₹42,21,56,320, consisting of 42,21,56,320 equity shares of ₹10 each, to ₹43,68,56,320, consisting of 43,68,56,320 equity shares of ₹10 each.

Astal Laboratories Limited has completed its quarterly regulatory compliance by submitting the required certificate under SEBI (Depositories and Participants) Regulation 2018 for the quarter ended March 31, 2026. The pharmaceutical company, formerly known as Macro International Limited, filed the mandatory documentation with BSE Limited on April 9, 2026.

Regulatory Compliance Details

The submission pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018, which mandates quarterly reporting by registrar and share transfer agents. The certificate was prepared and issued by BEETAL Financial & Computer Services (P) Ltd, the company's appointed registrar and share transfer agent.

Certificate Confirmation

BEETAL Financial & Computer Services confirmed that all securities received from depository participants for dematerialization during the quarter ended March 2026 were properly processed and confirmed to the depositories. The registrar verified that:

• Securities received for dematerialization were confirmed (accepted/rejected) to depositories
• Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within 15 days

Company Information

Astal Laboratories Limited operates with its registered office in Noida, Uttar Pradesh, and corporate office in Gachibowli, Telangana. The company secretary and compliance officer Mahendra Kumar digitally signed the submission document, ensuring proper authorization and compliance with regulatory requirements.

SEBI Regulatory Framework

The certificate submission aligns with SEBI circulars including NSDL/CIR/II/5/2019 dated January 25, 2019, CDSL/OPS/RTA/POLCY/2019/14 dated January 25, 2019, and SEBI letter ref no.MRD/DOP2/DSA2/OW/2019/2498/1 dated January 24, 2019. These guidelines ensure proper handling of dematerialized securities and maintain transparency in depositories operations.